INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alibaba Group Holding Limited - BABA
Sentiment Analysis
Pomerantz LLP is investigating claims on behalf of investors of Alibaba Group Holding Limited (“Alibaba” or the “Company”) (NYSE: BABA).
Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Alibaba and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On June 24, 2026, the Financial Times reported that Anthropic has accused Alibaba “of obtaining illicit access to Claude by creating fake accounts designed to access the AI model which the American company does not offer to Chinese groups.”
On this news, Alibaba’s American Depositary Receipt (“ADR”) price fell $7.53 per ADR, or 7.34%, over the following two trading sessions, to close at $95.07 per ADR on June 25, 2026.
Then, on July 1, 2026, the U.S. Department of Justice issued a press release announcing that Alibaba had “entered a non-prosecution agreement to pay $600 million to resolve the Justice Department’s allegations that they violated the Federal Food, Drug, and Cosmetic Act (FDCA) by failing to prevent merchants from selling and importing illegal pharmaceuticals, controlled substances, listed chemicals, and pill presses into the United States” through Alibaba’s e-commerce platforms.
On this news, Alibaba’s ADR price fell $1.85 per ADR, or 1.9%, to close at $96.14 per ADR on July 2, 2026.
Source: GlobeNewsWire
This content is not intended as investment advice or a recommendation. Any opinions expressed are solely the personal views of each article.